Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
Authors' conclusion
Use of GLP-1 RAs/SGLT2is in patients with T2D and ASCVD has increased in recent years in the USA, but remains suboptimal given the prevalence of ASCVD and its high morbidity and mortality.
Study context
- Population
- Patients with T2D and atherosclerotic cardiovascular disease (ASCVD) in the USA (TriNetX Dataworks-USA network)279,474 to 348,997 per year
- Outcome
- Yearly prevalent use of GLP-1 RA and SGLT2i
- Follow-up
- 2018 to 2022
Methodological detailsreal-world, longitudinal analysis of cross-sectional data, nested cohort study, de-identified data from TriNetX Dataworks-USA network
- Real-world
- Longitudinal analysis of cross-sectional data
- Nested cohort study
- De-identified data from TriNetX Dataworks-USA network
Main finding
As reported in the abstract
Prevalent use of GLP-1 RA and/or SGLT2i
GLP-1 RA and/or SGLT2i, 2018
9.2%
GLP-1 RA and/or SGLT2i, 2022
27.1%
GLP-1 RA alone, 2018 to 2022
5.2% to 9.9%
SGLT2i alone, 2018 to 2022
2.8% to 12.2%
Observational data: associations, not effects.
Further findings
Incident use within the year after ASCVD diagnosis · 2018-2022
- GLP-1 RA and/or SGLT2i
- 5.9% to 17.0%
- GLP-1 RA alone
- 3.6% to 7.8%
- SGLT2i alone
- 1.8% to 7.0%
- Nested cohort study
Original publication
Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. BMJ Open Diabetes Res Care. Published 4 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →